Lifecore Biomedical
LFCR

$5.62

8.08%

Market Cap: $174M

About: Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that offers differentiated capabilities in the development, filling, and finishing of complex sterile injectable pharmaceutical products in syringes and vials. It manufactures injectable-grade Hyaluronic Acid. Lifecore recognizes revenue in two different product categories, CDMO and fermentation.

Employees: 524

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,710 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

157% more call options, than puts

Call options by funds: $537K | Put options by funds: $209K

15% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 20

1% more capital invested

Capital invested by funds: $119M [Q1] → $119M (+$801K) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 4 [Q1] → 4 (+0) [Q2]

4% less funds holding

Funds holding: 77 [Q1] → 74 (-3) [Q2]

6.53% less ownership

Funds ownership: 73.15% [Q1] → 66.62% (-6.53%) [Q2]

14% less first-time investments, than exits

New positions opened: 19 | Existing positions closed: 22

See Fund Rankings

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target

$8

42%

upside

Avg. target

$8

42%

upside

High target

$8

42%

upside

1 analyst rating

1 positive

100%

0 neutral

0%

0 negative

0%

Craig-Hallum

Matthew Hewitt

0 / 0 met price target

42%upside

$8

Buy

Initiated

5 Sept 2024

See Analyst Rankings

Financial journalist opinion

Based on 121 articles about LFCR published over the past 30 days

Lifecore Biomedical, Inc. Is Being Sued For Securities Law Violations And Affected Shareholders Are Urged To Help The Schall Law Firm

LOS ANGELES, CA / ACCESSWIRE / September 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 7, 2020 and March 19, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 27, 2024.

Lifecore Biomedical, Inc. Is Being Sued For Securities Law Violations And Affected Shareholders Are Urged To Help The Schall Law Firm

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Lifecore

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Lifecore To Contact Him Directly To Discuss Their Options

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Lifecore

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Lifecore Biomedical, Inc. of Class Action Lawsuit and Upcoming Deadlines - LFCR

NEW YORK, NY / ACCESSWIRE / September 19, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or the "Company") (NASDAQ:LFCR) and certain officers. The class action, filed in the United States District Court for the District of Minnesota, and docketed under 24-cv-03028, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Lifecore securities between October 7, 2020, and March 19, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Lifecore Biomedical, Inc. of Class Action Lawsuit and Upcoming Deadlines - LFCR

LFCR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Lifecore Biomedical, Inc. Investors Have Opportunity to Lead Class Action Lawsuit!

NEW YORK, NY / ACCESSWIRE / September 19, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Lifecore securities between October 7, 2020, and March 19, 2024, inclusive (the "Class Period").

LFCR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Lifecore Biomedical, Inc. Investors Have Opportunity to Lead Class Action Lawsuit!

Lifecore Biomedical Announces High-Speed, Multi-Purpose 5-Head Isolator Filler is GMP-Ready and Operational

Installation and Qualification Successfully Completed for Closed-System Filler for Pre-Filled Syringes, Vials, and Cartridges

Lifecore Biomedical Announces High-Speed, Multi-Purpose 5-Head Isolator Filler is GMP-Ready and Operational

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Lifecore Biomedical, Inc. (LFCR)

LOS ANGELES, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming September 27, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Lifecore Biomedical, Inc. (“Lifecore” or the “Company”) (NASDAQ: LFCR) securities between October 7, 2020 and March 19, 2024, inclusive (the “Class Period”).

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Lifecore Biomedical, Inc. (LFCR)

The Schall Law Firm Invites Investor Participation In A Securities Fraud Case Against Lifecore Biomedical Inc

LOS ANGELES, CA / ACCESSWIRE / September 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 7, 2020 and March 19, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 27, 2024.

The Schall Law Firm Invites Investor Participation In A Securities Fraud Case Against Lifecore Biomedical Inc

LFCR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Lifecore Biomedical, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit!

NEW YORK, NY / ACCESSWIRE / September 18, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Lifecore securities between October 7, 2020, and March 19, 2024, inclusive (the "Class Period").

LFCR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Lifecore Biomedical, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit!

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Lifecore Biomedical, Inc. of Class Action Lawsuit and Upcoming Deadlines - LFCR

NEW YORK , Sept. 17, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or the "Company") (NASDAQ: LFCR) and certain officers.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Lifecore Biomedical, Inc. of Class Action Lawsuit and Upcoming Deadlines - LFCR

LFCR Deadline: LFCR Investors Have Opportunity to Lead Lifecore Biomedical, Inc. Securities Fraud Lawsuit

NEW YORK , Sept. 17, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Lifecore Biomedical, Inc. (NASDAQ: LFCR) between October 7, 2020 and March 19, 2024, both dates inclusive (the "Class Period"), of the important September 27, 2024 lead plaintiff deadline.

LFCR Deadline: LFCR Investors Have Opportunity to Lead Lifecore Biomedical, Inc. Securities Fraud Lawsuit

See News Rankings